{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:28:23Z","timestamp":1786451303594,"version":"build-2736575974"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:00:00Z","timestamp":1452470400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ebiom.2016.01.010","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T15:02:04Z","timestamp":1452783724000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"3","author":[{"given":"Jason B.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady L.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas C.","family":"Platanias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0010","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.010_bb0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ebiom.2016.01.010_bb0020","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.exphem.2012.04.007","article-title":"The HDAC inhibitor givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2 V617F Myeloproliferative Neoplasm Cells","volume":"40","author":"Amaru Calzada","year":"2012","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.010_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.exphem.2012.10.013","article-title":"Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients","volume":"41","author":"Amaru Calzada","year":"2013","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.010_bb0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.010_bb0035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.010_bb0040","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.010_bb0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"23","key":"10.1016\/j.ebiom.2016.01.010_bb0050","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: a international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ebiom.2016.01.010_bb0055","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2147\/OTT.S31916","article-title":"Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis","author":"Barosi","year":"2015","journal-title":"OncoTargets Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.ebiom.2016.01.010_bb0060","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/j.clml.2013.07.011","article-title":"Rationale for targeting the PI3K\/Akt\/mTOR pathway in myeloproliferative neoplasms","volume":"13","author":"Bartalucci","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.010_bb0065","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J. Cell. Mol. Med."},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.010_bb0070","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V122.21.666.666","article-title":"Improved efficacy of combination Of JAK2 and hedgehog inhibitors in myelofibrosis N. Bhagwat, ed","volume":"122","author":"Bhagwat","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ebiom.2016.01.010_bb0075","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ebiom.2016.01.010_bb0080","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"120","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2016.01.010_bb0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/eji.201444862","article-title":"BET bromodomain inhibition suppresses transcriptional responses to cytokine-Jak\u2013STAT signaling in a gene-specific manner in human monocytes","volume":"45","author":"Chan","year":"2015","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.010_bb0090","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/jcmm.12156","article-title":"Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors","volume":"17","author":"Choong","year":"2013","journal-title":"J. Cell. Mol. Med."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0095","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.010_bb0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12384","article-title":"Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis","volume":"162","author":"Deangelo","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ebiom.2016.01.010_bb0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","author":"Deininger","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ebiom.2016.01.010_bb0110","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in Myeloid Cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.ebiom.2016.01.010_bb0115","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ebiom.2016.01.010_bb0120","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.010_bb0125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.ebiom.2016.01.010_bb0130","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN a-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.010_bb0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood.V122.21.109.109","article-title":"Aurora a kinase is a novel therapeutic target in the myeloproliferative neoplasms Q. J. Wen, ed","volume":"122","author":"Goldenson","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.010_bb0140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11899-013-0178-x","article-title":"The new landscape of therapy for myelofibrosis","volume":"8","author":"Gowin","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"8","key":"10.1016\/j.ebiom.2016.01.010_bb0145","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.010_bb0150","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V124.21.712.712","article-title":"Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis","volume":"124","author":"Gupta","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0155","doi-asserted-by":"crossref","first-page":"A669","DOI":"10.1016\/j.jval.2015.09.2446","article-title":"Cost-effectiveness of ruxolitinib for the treatment of myelofibrosis in Finland. Economic evaluation based on finnish auria biobank data on health care resource utilization","volume":"18","author":"Hahl","year":"2015","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.010_bb0160","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ebiom.2016.01.010_bb0165","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","article-title":"Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0170","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.010_bb0175","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.1951","article-title":"Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms","volume":"5","author":"Huang","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.010_bb0180","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","article-title":"Efficacy and safety of pegylated-interferon \u03b1-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups","volume":"162","author":"Ianotto","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.010_bb0185","first-page":"424","article-title":"Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies","volume":"118","author":"Jamieson","year":"2011","journal-title":"ASH Ann. Meet. Abstr."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.010_bb0190","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjh.13426","article-title":"Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?","volume":"170","author":"Khan","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.010_bb0195","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund UK"},{"issue":"8","key":"10.1016\/j.ebiom.2016.01.010_bb0200","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.ebiom.2016.01.010_bb0205","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.ebiom.2016.01.010_bb0210","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ebiom.2016.01.010_bb0215","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","article-title":"Results of a phase 2 study of pacritinib (SB1518 ), a JAK2\/JAK2 (V617F) inhibitor, in patients with myelo fi brosis","volume":"125","author":"Komrokji","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.010_bb0220","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1172\/JCI74182","article-title":"Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm","volume":"124","author":"Kong","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ebiom.2016.01.010_bb0225","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ebiom.2016.01.010_bb0230","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.010_bb0235","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1182\/blood.V124.21.4575.4575","article-title":"Pims: potential therapeutic targets for myeloproliferative neoplasms","volume":"124","author":"Lambert","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ebiom.2016.01.010_bb0240","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.010_bb0245","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.010_bb0250","first-page":"CD010298","article-title":"Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis","volume":"4","author":"Marti-Carvajal","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.010_bb0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13148-011-0050-6","article-title":"Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies","volume":"2","author":"Mascarenhas","year":"2011","journal-title":"Clin. Epigenetics"},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.010_bb0260","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jcmm.12202","article-title":"Combination therapies in myeloproliferative neoplasms: Why do we need them and how to identify potential winners?","volume":"17","author":"Mclornan","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ebiom.2016.01.010_bb0265","article-title":"Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial","volume":"2","author":"Mead","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.010_bb0270","first-page":"4704","article-title":"Need for patient reported outcomes (PRO) in adult acute lymphoblastic leukemia (ALL)","volume":"120","author":"Mehta","year":"2012","journal-title":"ASH Ann. Meet. Abstr."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.010_bb0275","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.molmed.2012.11.006","article-title":"Telomerase and the search for the end of cancer","volume":"19","author":"Mocellin","year":"2013","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0280","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1517\/14656566.2014.899582","article-title":"Use of mTOR inhibitors in the treatment of malignancies","volume":"15","author":"Mohindra","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ebiom.2016.01.010_bb0285","series-title":"Hematology\/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program","first-page":"287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","author":"Nangalia","year":"2014"},{"issue":"25","key":"10.1016\/j.ebiom.2016.01.010_bb0290","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.010_bb0295","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-12-0735","article-title":"Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms","volume":"73","author":"Nischal","year":"2013","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0300","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1582-4934.2011.01279.x","article-title":"Targeting telomerase-expressing cancer cells","volume":"15","author":"Ouellette","year":"2011","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.010_bb0305","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-015-0388-z","article-title":"Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms","volume":"14","author":"Pandey","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ebiom.2016.01.010_bb0310","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 Inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0315","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.010_bb0320","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/leu.2008.91","article-title":"A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"22","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.010_bb0325","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","article-title":"Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis","volume":"36","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.010_bb0330","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.010_bb0335","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.010_bb0340","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.beha.2014.07.001","article-title":"A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms","volume":"27","author":"Rampal","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.010_bb0345","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"Thrombocythemia with substantially different clinical course and outcomes JAK2 or CALR mutation status de fi nes subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0350","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.010_bb0355","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1182\/blood.V122.21.4100.4100","article-title":"The combination of JAK inhibitor, ruxolitinib, and PIM inhibitor, LGH447, in preclinical models of myeloproliferative neoplasia Z. Alexander Cao, ed","volume":"122","author":"Saci","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.010_bb0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.it.2014.10.006","article-title":"Intersection of mTOR and STAT signaling in immunity","volume":"36","author":"Saleiro","year":"2014","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0365","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3109\/10428194.2014.984703","article-title":"Phase II evaluation of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis","volume":"56","author":"Sasaki","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.010_bb0370","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10428194.2011.597905","article-title":"Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"53","author":"Skov","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"503","key":"10.1016\/j.ebiom.2016.01.010_bb0375","doi-asserted-by":"crossref","first-page":"195","DOI":"10.17219\/acem\/32934","article-title":"Pro-apoptotic activity of ruxolitinib alone and in combination with hydroxyurea, busulphan, and PI3K\/mTOR inhibitors in JAK2-positive human cell lines","volume":"24","author":"Szyma\u0144ska","year":"2015","journal-title":"Adv. Clin. Exp. Med."},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.010_bb0380","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"17","key":"10.1016\/j.ebiom.2016.01.010_bb0385","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"issue":"27","key":"10.1016\/j.ebiom.2016.01.010_bb0390","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","article-title":"Pomalidomide is active in the treatment of anemia associated with myelofibrosis","volume":"27","author":"Tefferi","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.010_bb0395","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.010_bb0400","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.010_bb0405","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.010_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.010_bb0415","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ebiom.2016.01.010_bb0420","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.010_bb0425","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ebiom.2016.01.010_bb0430","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon \u2014 a therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2016.01.010_bb0435","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.010_bb0440","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.ebiom.2016.01.010_bb0445","first-page":"7114","article-title":"Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results","volume":"32","author":"Verstovsek","year":"2014","journal-title":"ASCO Meet. Abstr."},{"issue":"November","key":"10.1016\/j.ebiom.2016.01.010_bb0450","first-page":"1","article-title":"Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis","volume":"24","author":"Verstovsek","year":"2015","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.ebiom.2016.01.010_bb0455","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.010_bb0460","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40273-013-0083-0","article-title":"Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal","volume":"31","author":"Wade","year":"2013","journal-title":"PharmacoEconomics"},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.010_bb0465","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190802527699","article-title":"Enhanced histone deacetylase enzyme activity in primary myelofibrosis","volume":"49","author":"Wang","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"24","key":"10.1016\/j.ebiom.2016.01.010_bb0470","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ebiom.2016.01.010_bb0475","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1182\/blood-2010-02-269696","article-title":"Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD\/SCID marrow repopulating cells","volume":"116","author":"Wang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ebiom.2016.01.010_bb0480","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2015.03.001","article-title":"PIM kinase (and Akt) biology and signaling in tumors","volume":"151","author":"Warfel","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.010_bb0485","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.010_bb0490","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.010_bb0495","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3324\/haematol.2013.095109","article-title":"Resolution of Bone marrow fibrosis in a patient receiving JAK1\/JAK2 inhibitor treatment with ruxolitinib","volume":"98","author":"Wilkins","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ebiom.2016.01.010_bb0500","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/leu.2013.234","article-title":"BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms","author":"Wyspianska","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.010_bb0505","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.leukres.2015.01.009","article-title":"Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2\/STAT signaling in myeloproliferative neoplasm","volume":"39","author":"Yin","year":"2015","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.010_bb0510","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bcmd.2015.07.007","article-title":"Targeting glutamine metabolism in myeloproliferative neoplasms","volume":"55","author":"Zhan","year":"2015","journal-title":"Blood Cell Mol. Dis."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641630007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641630007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T20:13:24Z","timestamp":1718309604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239641630007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":102,"alternative-id":["S235239641630007X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.01.010","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}